Table 1.
Hyperprogession incidence among atezolizumab-treated cohorts by line of treatment, histotype, and treatment-arm.
| Line of treatment | Cancer histotype | Treatment arm | HPD/total no. (%) |
|---|---|---|---|
| First-line | 13/1919 (0.7) | ||
| Squamous | 2/646 (0.3) | ||
| Non-squamous | 11/1273 (0.9) | ||
| ABCP | 2/356 (0.6) | ||
| ACP | 5/674 (0.7) | ||
| ACnP | 3/743 (0.4) | ||
| Atez | 3/146 (2.1) | ||
| Second-line | 75/807 (9.3) | ||
| Squamous | 23/229 (10.0) | ||
| Non-squamous | 52/578 (9.0) | ||
| Atez | 75/807 (9.3) | ||
| Third- and later-later | 31/403 (7.7) | ||
| Squamous | 7/99 (7.1) | ||
| Non-squamous | 24/304 (7.9) | ||
| Atez | 31/403 (7.7) |
Abbreviations: ABCP: atezolizumab + bevacizumab +carboplatin + paclitaxel; ACP: atezolizumab + carboplatin + paclitaxel; ACnP: atezolizumab + carboplatin + nab-paclitaxel; Atez: atezolizumab monotherapy; HPD: hyperprogression.